Aktiesnakken — November 2009
-
omvendt vil det være svært hvis genmab står med en billion dollar partner?
-
fordi hvis egfr blivr partnered ud får man jo ikke hele værdien af stoffet med gratis
-
gsk skal da prøve nu med kurs 300
-
tænk medarex
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind